Clinical monitoring of activated clotting time during cardiothoracic surgery: comparing the Hemochron® Response and Hemochron® Signature Elite

Introduction: The Activated Clotting Time (ACT) is commonly used to manage anticoagulation during cardiac surgery. The aim of this study was to compare the older manually operated Hemochron® Response and the automated Hemochron® Signature Elite. Methods: In this observational study the clinically relevant differences of both devices were investigated simultaneously, using duplicate measurements, in 29 patients who underwent a Coronary Artery Bypass Grafting (CABG) or Aortic Valve Replacement (AVR) in order to determine reliability, bias, and to detect which method has the lowest variation. Blood samples were obtained from the arterial line prior to surgery, after administration of 300 IU/kg heparin, 5 minutes after initiation of cardiopulmonary bypass and successively every 30 minutes, and after protamine administration. Results: A total of 202 measurements were performed. Of these 10 measurements were out of range in the Response and 9 in the Elite. About 27 single unstable magnet errors were seen in the Response versus no measurement errors in the Elite. No statistically significant differences between the Response (p = 0.22, Wilcoxon rank) and Elite (p = 0.064) duplicates were observed. The Response values were consistently higher during heparinization than the Elite measurements (p = 0.002, repeated measurements) with an average positive bias of around 56 seconds during heparinization (Bland-Altman). Overall, the coefficient of variation (CoV) increased during heparinization. Conclusion: The Elite was more reliable, but the variation was higher for the Elite than the Response. The observed positive bias in the Response compared to the Elite could affect heparin administration during surgery making the two systems not interchangeable.

[1]  S. Emani,et al.  Transition from Hemochron Response to Hemochron Signature Elite Activated Clotting Time Devices in a Congenital Cardiac Surgery Practice. , 2019, The journal of extra-corporeal technology.

[2]  Raja R. Palvadi,et al.  Society of Cardiovascular Anesthesiologists Clinical Practice Improvement Advisory for Management of Perioperative Bleeding and Hemostasis in Cardiac Surgery Patients. , 2019, Journal of cardiothoracic and vascular anesthesia.

[3]  S. Emani,et al.  High-dose heparin is associated with higher bleeding and thrombosis rates in pediatric patients following cardiac surgery. , 2019, The Journal of thoracic and cardiovascular surgery.

[4]  G. Lippi,et al.  Analytical Assessment of the New Roche Cobas t 711 Fully Automated Coagulation Analyzer , 2019, Seminars in Thrombosis and Hemostasis.

[5]  V. Bhatt,et al.  Reversal of Anticoagulation and Management of Bleeding in Patients on Anticoagulants , 2017, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[6]  E. R. van den Heuvel,et al.  The activated clotting time in cardiac surgery: should Celite or kaolin be used? , 2017, Interactive cardiovascular and thoracic surgery.

[7]  A. Shah,et al.  Interchangeability of activated clotting time values across different point-of-care systems. , 2012, The American journal of cardiology.

[8]  F. Sztark,et al.  Validation of a bedside activated clotting time test (Hemochron® Jr II Signature) with low dose heparin therapy , 2009, Anaesthesia.

[9]  M. Appelblad,et al.  Measurement of the activated clotting time during cardiopulmonary bypass: differences between Hemotec® ACT and Hemochron® Jr apparatus , 2004, Perfusion.

[10]  J. Hirsh,et al.  Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[11]  V. Disesa,et al.  New technology, old standards: disparate activated clotting time measurements by the Hemochron Jr compared with the standard Hemochron. , 2004, The Annals of thoracic surgery.

[12]  M. Stafford-Smith,et al.  Activated Clotting Time Systems Vary In Precision And Bias And Are Not Interchangeable When Following Heparin Management Protocols During Cardiopulmonary Bypass , 2002, Journal of Clinical Monitoring and Computing.

[13]  C. Kessler,et al.  Consultative Hemostasis and Thrombosis , 2002 .

[14]  G. Gravlee,et al.  Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques. , 1999, Anesthesiology.

[15]  M. Abdelnoor,et al.  Assessment of heparin anticoagulation: comparison of two commercially available methods. , 1999, The Annals of thoracic surgery.

[16]  R. Blumenthal,et al.  Clinical evaluation of a microsample coagulation analyzer, and comparison with existing techniques. , 1996, Catheterization and cardiovascular diagnosis.

[17]  W. van Oeveren,et al.  In vitro effect of hemodilution on activated clotting time and high-dose thrombin time during cardiopulmonary bypass. , 1996, The Annals of thoracic surgery.

[18]  J. Horrow,et al.  Activated coagulation time: one tube or two? , 1994, Journal of cardiothoracic and vascular anesthesia.

[19]  G. Gravlee,et al.  Variability of the activated coagulation time. , 1988, Anesthesia and analgesia.

[20]  R. Pifarré,et al.  Monitoring of intraoperative heparinization and blood loss following cardiopulmonary bypass surgery. , 1977, The Journal of thoracic and cardiovascular surgery.

[21]  B. Bull,et al.  Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. , 1975, The Journal of thoracic and cardiovascular surgery.

[22]  P. Hattersley The activated coagulation time of whole blood as a routine pre-operative sceening test. , 1971, California medicine.

[23]  P. Hattersley Activated coagulation time of whole blood. , 1966, JAMA.

[24]  M. Lancé,et al.  ECMO and anticoagulation : a comprehensive review , 2018 .

[25]  J. Lammers,et al.  Double-blind prospective study comparing two automated sperm analyzers versus manual semen assessment , 2013, Journal of Assisted Reproduction and Genetics.

[26]  J. Horrow,et al.  Modified microsample ACT test for heparin monitoring , 1996 .

[27]  M. Laato,et al.  Use of activated clotting time to monitor anticoagulation during cardiac surgery. , 1984, Scandinavian journal of thoracic and cardiovascular surgery.